Kornimate/medical-research-clean huggingface dataset:
serum endocan levels and gestational diabetes

Conditions: Gestational Diabetes; Endocan

Summary: in diabetic patients, serum endocan level has been significantly increased in patients and the levels on the long-term complications are correlated. based on the iinformation obtained from these studies, it can be said that there is a strong association between diabetes and serum endocan levels.

it has been shown that endocan level of plasental tissue in gestational diabtes patients is significantly increased when looking at the same week compared with plasenta tissue samples of helathy pregnancy. from the information obtained from these studies, it can be said that there is a strong association between diabetes mellitus and serum endocan levels. investigators aimed to determine the relationship between serum endocan levels and gestational diabetes in the study.

Eligibility criteria:
inclusion criteria: * being pregnant at 24-26 weeks of gestation * having oral glucose toleranse screening test * age between 18-45 years exclusion criteria: * having in utero mort fetus * having a previous diagnosis of diabetes * having a multiple pregnancy * having a coronary artery disease * having preeclampcia * having a pregnancy obtained by assisted reproductive technology * using cigarette * using alcohol
mhealth intervention for work-related stress

Conditions: Work Related Stress

Summary: the objective of the trial is to pilot test the study protocol of a preventive, low-intensive mobile health (mhealth) intervention for work-related stress among nursing students. work stress is a wide-spread problem affecting individual health as well as incurring substantial societal costs. mhealth solutions are among the most promising options for providing effective, scalable, and standardized interventions to employees.

researchers generally agree that recovery is a key buffer against the negative consequences of stress. recovery behaviors, such as mindfulness and physical activity, are well-known to have a positive effect on stress-related health problems. for this reason, a behavior change intervention that successfully improves recovery may be effective in combating the long-term effects of stress. in this pilot study, three groups of participants received different versions of an intervention, each version containing a distinct set of recovery strategies. the motivation of the present study is to pilot test the intervention and a study protocol in preparation for a future randomized controlled trial (rct). pilot testing the intervention and study procedures at an early stage is critical to identify potential pitfalls that need to be addressed before conducting a full-scale trial. through investigating the study and intervention in preparatory phases we can refine the study protocol and intervention design in order to maximize the chances of a successful rct. the research questions for this pilot study are: 1. data collection procedure - what is the recruitment and retention rate of invited participants? does the randomization algorithm function properly? 2. engagement - how often do participants use the intervention? do they find the application easy and engaging to use? 3. acceptability - do participants find the intervention overall satisfactory and perceive it as beneficial? is the digital tool technically stable? 4. measurement quality - what is the completion rate for questionnaire items? what is the within-person variability in the daily measures?

Eligibility criteria:
inclusion criteria: * active employee or student. exclusion criteria: * no psychiatric disorder.

Keywords: work stress work-related stress occupational stress
humeral compression/distraction device

Conditions: Humeral Fractures

Summary: the proposed study of humeral shaft fractures in adults will examine outcomes in patients treated with the humeral trauma nail system to treat displaced humeral shaft fractures (displaced ota code 12a, b, or c), nonunions, or malunions. the device to be studied uses an internal gear system controlled wirelessly by rare earth magnets, which typically offers distraction for lengthening. in the humerus however, during the treatment of acute fractures, this percutaneously inserted nail can also offer compression during the healing process, thereby negating the effect of gravity, which may in turn lead to a faster and more consistent rate of union. furthermore, in cases of slower healing the dynamic properties of the nail may employ an "accordion technique" (alternating compression-distraction, a feature unique to this implant.

the primary end point will be the union rate without secondary procedures. the hypothesis is that with the compression and distraction that this device makes possible, the investigators can achieve a higher union rate than with other forms of treatment, using a percutaneous approach, with a decreased complication rate, and can dynamically modulate the healing response when needed. the primary safety endpoint is the occurrence of adverse events from the time of treatment. during the healing process an external remote controller (erc) will be used to continually compress or distract the fracture as needed. the surgeon will monitor healing and decide, clinically based on sequential radiographs during subsequent office visits, whether the fracture needs additional compression or distraction, an accordion technique, or no additional external manipulation via the erc. participants will be followed for 12 months.

Eligibility criteria:
inclusion criteria: * adult skeletally mature patients 18 years or older, treated by the orthopaedic trauma service at tampa general hospital, and the trauma service at st. louis university hospital * open or closed displaced humeral shaft fractures (displaced ota code 12a, b, or c), nonunions or malunions * amenable to treatment with an intramedullary nail exclusion criteria: * intra-articular extension of the fracture, prohibiting treatment with an intramedullary nail; * pathologic fracture * retained hardware * patients with pacemakers * age under 18 years. * patients who are prisoners or likely to become prisoners * homeless, or those likely to have difficulty making follow-up appointments * pregnancy * ipsilateral nerve or vascular injuries * immunocompromised patients

Keywords: upper extremity fracture
physical activity recommendation behaviour in german psychologists

Conditions: Mental Disorder; Physical Activity

Summary: the purpose of this study is to examine the physical activity recommendation behaviour, beliefs, barriers and exercise participation in german psychologists working with patients with mental disorders.

physical activity plays an important role in the prevention and treatment of mental disorders. despite the potential mental health benefits, large proportions of patients with mental disorders do not meet the physical activity recommendations. clinical psychologists play a key role in the recommendation of physical activity to their patients. there are no previous studies that examine physical activity recommendation behaviour in german psychologists. the purpose of this study is to examine the physical activity recommendation behaviour, beliefs, barriers and exercise participation in german psychologists working with patients with mental disorders.

Eligibility criteria:
inclusion criteria: * clinical psychologist * currently working with patients with mental disorders * at least 18 years old * sufficient german skills for answering the questionnaire exclusion criteria: none

Keywords: physical activity mental disorder recommendation behaviour prescription behaviour mental health exercise
honolulu heart program-study of stroke and dementia

Conditions: Cardiovascular Diseases; Cerebrovascular Accident; Cerebrovascular Disorders; Dementia

Summary: to clarify the relationship of the arterial lesions to aging, define the influence of the arterial changes on the development of stroke, brain infarction, and dementia, and provide a better understanding of vascular dementia.

background: morphologic delineation of the arterial lesions will assist the use of experimental models to study molecular mechanisms underlying the lesions and the development of pharmacologic methods for controlling these mechanisms. further examination of risk factors for the arterial lesions will indicate opportunities for prevention or modifying their evolution. design narrative: the study was based on data including risk factors and autopsy brain sections from deceased men from the honolulu heart program. in this cohort, medial and intimal lesions of brain parenchymal arteries were significantly associated with brain infarction and three times more common in men dying of stroke than of non-cardiovascular causes. the specific aims of the study were 1) delineation of the morphologic characteristics of the brain parenchymal artery lesions, their regional anatomic distribution, and their relationship to changes in adjacent brain parenchyma and the degree of atherosclerosis in the major intracranial arteries; 2) characterization of the relationship in men between the arterial lesions and advancing age; 3) characterization in men over 60-65 years of age of the relationship of the arterial lesions to stroke, brain infarction or hemorrhage, and dementia; 4) identification of additional risk factors associated with the arterial lesions. the arterial lesions and adjacent brain parenchyma were examined with conventional histologic stains and immunohistochemical markers for specific cellular and extracellular components of the arterial wall. the prevalence and extent of each type of arterial lesion were determined at three anatomic sites. baseline risk factors thought to be related to stroke and brain infarction were examined for association with the arterial lesions. statistical tests of association were based on univariate and multivariate linear and logistic regression models controlled, when necessary, for age. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
a study to investigate the safety, tolerability, drug levels and drug effects of bms-986326 in adult participants with different forms of lupus

Conditions: Lupus

Summary: the purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of bms-986326 via intravenous (iv) infusion or subcutaneous (sc) injection, in participants with different forms of lupus.


Eligibility criteria:
inclusion criteria: * having a diagnosis of discoid lupus erythematosus (dle), subacute cutaneous lupus erythematosus (scle), or systemic lupus erythematosus (sle). * participants with dle or scle must have their diagnosis at least 3 months prior to screening and must be confirmed by biopsy (except if only the facial/head/neck region is affected) and must have some ongoing disease activity (based clasi-a scoring). * participants with sle must have a diagnosis of sle at screening based on the 2019 eular/acr classification for sle and have mild-moderate disease severity (based on a sledai-2k score). exclusion criteria: * sle that is considered by the investigator to be severe. * drug-induced cle and drug-induced sle. * women who are pregnant or breastfeeding. * current use of \>10 mg prednisone (or equivalent) per day. note: other protocol-defined inclusion/exclusion criteria apply.

Keywords: pharmacokinetics bms-986326 cutaneous lupus discoid lupus erythematosus (dle) subacute cutaneous lupus erythematosus (scle) systemic lupus erythematosus (sle)
study to evaluate the efficacy and safety of ctp-543 in adults with moderate to severe alopecia areata (thrive-aa1)

Conditions: Alopecia Areata

Summary: this study evaluates the safety and effectiveness of an investigational study drug (called ctp-543) in adults (18 years and older) who have 50% or greater scalp hair loss.


Eligibility criteria:
inclusion criteria: * clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of screening. total disease duration greater than 10 years is permitted. * at least 50% scalp hair loss, as defined by a severity of alopecia tool (salt) score ≥50, at screening and baseline. * willing to comply with the study visits and requirements of the study protocol. exclusion criteria: * treatment with other medications or agents within 1 month of baseline or during the study that may affect hair regrowth or immune response. * active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the salt assessment, or untreated actinic keratosis anywhere on the body at screening and/or baseline. * treatment with systemic immunosuppressive medications within 3 months of screening or during the study, or biologics within 6 months of screening or during the study. * females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug. * clinically significant medical condition, psychiatric disease, or social condition, as determined by the investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

Keywords: alopecia hair loss hair disease ctp-543
biomarkers in saliva in children with juvenil idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis

Summary: purpose and aims this as a pilot study that aims to investigate which inflammatory biomarkers can be found in saliva in children with juvenile idiopathic arthritis (jia). the hypothesis is that children with jia will show a different pattern of inflammatory biomarkers in saliva than healthy children. the null hypothesis is that there are no differences.

this is a comparison between 100 children with jia and 100 healthy children. saliva will be collected and analyzed with respect to biomarkers. one-hundred consecutive patients with active jia, as diagnosed by the department of pediatric rheumatology, astrid lindgrens barnsjukhus, karolinska university hospital will be included. inclusion criteria are: * age between 7 and 14 years * a diagnosis of jia according to the international league of associations for rheumatology exclusion criteria are: * current malignancies * tmj surgery or trauma within two years * recent intra-articular glucocorticoid injection in tmj (within 1 month) * other conditions or diseases than jia that may cause orofacial pain. the parents of the patients and/or the patients will give their verbal and written informed consent to participate in the study according to the permission from the regional ethical committee 2011/2:1. the control group of 100 age and sex matched healthy children will be included at folktandvården stockholms län ab. inclusion criteria are: • age between 7 and 14 years exclusion criteria are: * current malignancies * tmj surgery or trauma within two years * recent intra-articular glucocorticoid injection in tmj (within 1 month) * a diagnosis of jia * other conditions or diseases than jia that may cause orofacial pain. the parents of the patients and/or the patients will give their verbal and written informed consent to participate in the study according to the permission from the regional ethical committee 2011/2:1.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of jia according to the international league of associations for rheumatology (ilar) the parents of the patients and/or the patients will give their verbal and written informed consent to participate in the study according to the permission from the regional ethical committee 2011/2:1 exclusion criteria: 1. current malignancies 2. tmj surgery or trauma within two years 3. recent intra-articular glucocorticoid injection in tmj (within 1 month) 4. other conditions or diseases than jia that may cause orofacial pain. fore the controllgroup jia are excluded

Keywords: juvenile idiopathic arthritis saliva
myocardial ischemia after coronary sinus reduction stent implantation

Conditions: Angina Pectoris

Summary: chronic angina pectoris refractory to medical and revascularization therapies is a disabling medical condition and a major public health problem. patients with refractory angina have limited treatment options. one proposed therapy modality is transcatheter implantation of a reduction stent in the coronary sinus. coronary sinus reduction stents have been shown to reduce angina burden considerably and to improve quality of life. the reduction stent is assumed to increase myocardial perfusion and reduce myocardial ischemia, but the mechanism of action is poorly understood. the aim of this project is to assess the myocardial ischemia burden in patients with refractory angina who are undergoing a transcatheter coronary sinus reducer procedure. this is a clinical non-randomized self-controlled cohort study with blinded outcome adjudication for changes in myocardial perfusion. patients with refractory angina will be systematically examined before implantation of the coronary sinus reduction stent and after 6 months. the primary outcome, changes in myocardial perfusion on the gold standard 15o-h2o pet/ct will be evaluated on blinded perfusion scans where the stent is invisible. to provide context to the findings, we will also evaluate whether changes in myocardial ischemia are associated with less angina and better cardiac function parameters. effects of stent implantation on angina symptoms and quality of life could be affected by a placebo effect. treatment options for patients with refractory angina is needed, and results from the present study will explore if coronary sinus reduction stents are improving myocardial ischemia in this patient group. signs of improved objective perfusion will inspire confidence in the method.


Eligibility criteria:
inclusion criteria: * coronary artery disease and refractory angina * clinical indication for coronary sinus reduction stent implantation * written informed consent * anticipated compliance with protocol exclusion criteria: * ineligibility for coronary sinus reduction stent implantation * lack of informed consent * not expected to comply with protocol
impedance measurements in heart failure patients

Conditions: Heart Failure

Summary: the purpose of this study is to measure impedance during inpatient treatment.


Eligibility criteria:
inclusion criteria: * patients admitted to hospital for symptoms of congestive heart failure * patients older than 18 years * patients willing and able to give informed consent exclusion criteria: * patients who will require adrenergic or positive inotropic medications * patients enrolled in a concurrent study that may confound the results of this study * patients unable or unwilling to participate in study procedures * patients who are pregnant * patients who are mentally handicapped or legal incompetent * patients who are dependent on investigator or sponsor

Keywords: heart failure hf
neural and visual responses to light in bipolar disorder: a novel putative biomarker

Conditions: Bipolar Depression

Summary: objective. bipolar disorders (bd) are a major public health problem. the investigators still lack knowledge of the mechanisms which contribute to bd. hence treatments are few and limited, and clinical decision making is less refined. currently, the investigators are investigating the effects of midday bright light therapy for the treatment of bipolar depression (university of pittsburgh irb approved protocol titled light therapy for bipolar disorder, irb#: pro09020546). in this study, the investigators propose to investigate a possible biological mechanism which might explain response to light treatment in depressed bipolar patients.

the study goal is to understand how the response to light therapy relates to changes in vision, brain function and improvement in bipolar symptoms. the aims are to investigate mood levels plus the eye and brain responses to visual contrast stimuli in healthy comparators (hc) and bipolar depressed patients. study design and methods. overview. the investigators plan to enroll 18-50 year old adults with bd type i or ii and a current episode of major depression on stable-dosed antimanic drugs, and age and sex-matched hc - without mental disorders. depressed patients with bd will be assigned randomly to receive active light therapy vs inactive comparator for 6 weeks. the investigators will examine responses to contrast stimuli from measures of visual evoked potentials and electro-retinography in hc and depressed bipolar patients before and after 6-weeks of daily midday light therapy. the investigators will assess repeated measures of mood symptom levels, attention and circadian rhythms.

Eligibility criteria:
inclusion criteria: * ages 18-50 years. * dsm-iv bd type i or ii, current major depressive episode * stable-dosed antidepressant drug for 4 weeks or more only with concurrent antimanic drug. * controlled thyroid disease. * subjects with preexisting eye diseases will be included specific exceptions are described in the exclusion criteria. * able to provide informed consent. * stable minimum dose of antimanic drug for 4weeks or more. * stable unchanged psychotherapy for 16 weeks or more. * permitted drugs for sleep at low doses. exclusion criteria: * certain specific eye diseases (retinal disease, untreated cataracts or macular degeneration) * photosensitizing drugs such as phenothiazines (chlorpromazine), antimalarial drugs, melatonin and hypericum. * acute psychosis (dsm-iv criteria) * rapid cycling in the past 1 year * alcohol or substance abuse or dependence in the past 6 months. * current symptoms of hypomania or mania i.e. maniaratingscale=5 * recent history of a suicide attempt (3 months) or active suicidal ideation (sigh-ads item h11=2 or more) * treatment with propranolol (inderal), exogenous melatonin, chronic nsaids.

Keywords: bipolar disorder depression light therapy contrast sensitivity visual evoked potential visual or neural responses biomarker
xarelto for prevention of stroke in patients with atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.


Eligibility criteria:
inclusion criteria: * female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-cns (central nervous system) systemic embolism, and who consent to participate in the study

Keywords: stroke embolism atrial fibrillation
a study evaluating the treatment selection and outcome when changing antipsychotic treatment in schizophrenic patients

Conditions: Schizophrenia

Summary: the purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in cgi-cb scale (clinical global impression - clinical benefit).


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia (as per dsm-iv), at least 6 months prior to enrolment in the study * subjects who have initiated a new antipsychotic treatment within the preceding 2 weeks * subjects whose prior and current antipsychotic treatment consists of any typical or atypical antipsychotic monotherapy exclusion criteria: * subjects fulfilling criteria for diagnosis of any other psychiatric condition (except from schizophrenia), as per dsm-iv axis ι, concomitant organic mental disorder or mental retardation * substance abuse or dependence (with the exception of nicotine dependence), as defined by dsm-iv criteria and not in full remission * female subjects who are pregnant or lactating

Keywords: schizophrenia switch of antipsychotic treatment outcome evaluation monotherapy greece